John Ryan - Nov 9, 2021 Form 4 Insider Report for Kadmon Holdings, Inc. (KDMN)

Role
EVP, Chief Medical Officer
Signature
/s/ Gregory S. Moss, Attorney-in-Fact
Stock symbol
KDMN
Transactions as of
Nov 9, 2021
Transactions value $
-$3,200,875
Form type
4
Date filed
11/9/2021, 04:41 PM
Previous filing
Jul 12, 2021
Next filing
Sep 7, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KDMN Stock Option (right to buy) Disposed to Issuer -$484K -100K -100% $4.84 0 Nov 9, 2021 Common Stock, par value $0.001 100K $4.66 Direct F1, F2
transaction KDMN Stock Option (right to buy) Disposed to Issuer -$879K -150K -100% $5.86 0 Nov 9, 2021 Common Stock, par value $0.001 150K $3.64 Direct F1, F2
transaction KDMN Stock Option (right to buy) Disposed to Issuer -$352K -50K -100% $7.03 0 Nov 9, 2021 Common Stock, par value $0.001 50K $2.47 Direct F1, F2
transaction KDMN Stock Option (right to buy) Disposed to Issuer -$516K -100K -100% $5.16 0 Nov 9, 2021 Common Stock, par value $0.001 100K $4.34 Direct F1, F2
transaction KDMN Stock Option (right to buy) Disposed to Issuer -$970K -175K -100% $5.54 0 Nov 9, 2021 Common Stock, par value $0.001 175K $3.96 Direct F1, F2
transaction KDMN Equity Appreciation Rights Unit Disposed to Issuer -$875 -250 -100% $3.50 0 Nov 9, 2021 Common Stock, par value $0.001 250 $6.00 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

John Ryan is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 In connection with the acquisition by Sanofi of the entire issued share capital of Issuer on November 9, 2021 by means of a plan of merger, all unvested stock options ("Options") and equity appreciation rights ("EARs") were accelerated to full vesting and cancelled in exchange for a payment equal to $9.50 with respect to each share of Common Stock subject to such Option and EAR award.
F2 Represents the payment per share of Common Stock received in exchange for the cancellation of each Option and EAR.